Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of tremelimumab ± durvalumab in Japanese patients with advanced solid tumors or malignant mesothelioma
jRCT2080222502Phase 1
- Sponsor
- AstraZeneca
- Start
- May 2014
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of tremelimumab and durvalumab in Non-hematologic malignancy, pleural mesothelioma and peritoneal mesothelioma (3 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of tremelimumab ± durvalumab, Pharmacokinetics of tremelimumab ± durvalumab and 1 more.
02
Drugs
tremelimumabdurvalumab
03
Conditions
Non-hematologic malignancypleural mesotheliomaperitoneal mesothelioma
Beyond the preview
Go deeper on jRCT2080222502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222502.